RenovoRx, Inc. (RNXT) intrinsic value & 10-year financials
RenovoRx, Inc. (RNXT) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 2511.6% a year to $1.1M, with an average return on invested capital of 494.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.14
- Market cap
- $40.3M
- Revenue (FY2025)
- $1.1M
- Revenue growth (7-yr CAGR)
- 2511.6%
- ROIC (10-yr avg)
- 494.8%
- Free cash flow (FY2025)
- -$11.0M
RNXT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.1M | -$11.2M | -$0.32 | -$11.0M | -1114.0% | 632.0% |
| FY2024 | $43.0K | -$8.8M | -$0.40 | -$9.1M | -25511.6% | 357.7% |
| FY2023 | — | -$10.2M | -$0.99 | — | — | — |
| FY2022 | — | -$9.9M | -$1.09 | — | — | — |
| FY2021 | — | -$6.3M | — | — | — | — |
| FY2020 | — | -$3.8M | — | — | — | — |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RenovoRx, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
RenovoRx, Inc. has historically struggled to out-earn its cost of capital, averaging just 4.9% ROIC.
RenovoRx, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, RenovoRx, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-10.63 per share.